New drug cocktail aims to control bladder cancer before surgery

NCT ID NCT05394337

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a combination of two drugs, atezolizumab and tiragolumab, can help control bladder cancer when given before surgery to remove the bladder and tumor. The study includes 10 adults with muscle-invasive bladder cancer who cannot take standard chemotherapy. Researchers will track how long participants stay cancer-free and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and tiragolumab (given by IV)
What this could lead to: If it works, this could point toward a new pre-surgery treatment option for bladder cancer patients who cannot take standard chemotherapy.
What could go wrong: This is a very small, early-phase trial with only 10 participants, so results may not apply widely. The combination may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma metastatic malignant neoplasm metastatic neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANCY

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.